Literature DB >> 1103724

Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin.

E L Goodman, J Van Gelder, R Holmes, A R Hull, J P Sanford.   

Abstract

In patients with impaired renal function, careful adjustment of gentamicin dosage is required to achieve therapeutic yet nontoxic concentrations. Two regimens that differ in pharmacodynamic characteristics have been recommended for this purpose: prolonging the intervals between administration of equal doses (variable frequency regimen [VFR]) or administering a loading dose followed at the usual intervals by reduced maintenance doses (variable dosage regimen [VDR]). These regimens were compared in a prospective, randomized study of 20 seriously ill hospitalized patients, 10 on VFR and 10 on VDR. Wide variability in peak serum levels of gentamicin was observed both between patients and in individual patients after separate injections of the same dosage. As predicted by the design of these regimens, the trough serum levels of gentamicin correlated significantly with the serum creatinine concentrations in patients on the VDR but not in patients on the VFR. A gentamicin trough level of >/=4 mug/ml was the only variable among those tested that correlated significantly with development or progression of renal insufficiency during treatment with gentamicin, but such trough levels were observed frequently on both regimens. Whereas this study does not permit a direct comparison of the therapeutic efficacy of VDR and VFR, no difference in the risk of nephrotoxicity with these regimens was observed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1103724      PMCID: PMC429365          DOI: 10.1128/AAC.8.4.434

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Dose of gentamicin in patients with normal renal function and renal impairment.

Authors:  J C Gingell; P M Waterworth
Journal:  Br Med J       Date:  1968-04-06

2.  Letter: Creatinine clearance: bedside estimate.

Authors:  R W Jelliffe
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

3.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

4.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

5.  Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States.

Authors:  G G Jackson; G Arcieri
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Pharmacology of gentamicin in man.

Authors:  L J Riff; G G Jackson
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

7.  Clinical research experience with gentamicin. Incidence of adverse reactions.

Authors:  G M Arcieri; F G Falco; H M Smith; L B Hobson
Journal:  Med J Aust       Date:  1970-06-13       Impact factor: 7.738

8.  Gentamicin therapy in renal failure: a nomogram for dosage.

Authors:  R A Chan; E J Benner; P D Hoeprich
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

9.  Relation between dose and levels of gentamicin in blood.

Authors:  R E Winters; K D Litwack; W L Hewitt
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

10.  Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration.

Authors:  M C McHenry; T L Gavan; R W Gifford; N A Geurkink; R A Van Ommen; M A Town; J G Wagner
Journal:  Ann Intern Med       Date:  1971-02       Impact factor: 25.391

View more
  24 in total

1.  Serum levels of gentamicin at peak and trough in neonates and infants.

Authors:  M Shahidullah; M Q Talukder; A K Chowdhury; S Ali; A Rashid
Journal:  Indian J Pediatr       Date:  1991 Mar-Apr       Impact factor: 1.967

2.  Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Yusuke Tanigawara; Reiko Sato; Kunihiko Morita; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

Authors:  M H Ensom; G A Davis; C D Cropp; R J Ensom
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

4.  Determination of kanamycin concentration in serum by substrate-labeled fluorescent immunoassay.

Authors:  A F DeCastro; J D Place; C T Lam; C Patel
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

5.  Plasma beta 2 microglobulin as a means of predicting gentamicin serum concentrations.

Authors:  J Valsamis; H Brauman; E Yourassowsky
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

Review 6.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

7.  Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).

Authors:  Julie M Varghese; Jason A Roberts; Steven C Wallis; Robert J Boots; Helen Healy; Robert G Fassett; Jeffrey Lipman; Dwarakanathan Ranganathan
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

Review 8.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 9.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Time course of trough serum gentamicin concentrations in preterm and term neonates.

Authors:  M A de Cos; J Gómez-Ullate; F Gómez; J A Armijo
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.